Risperidone Treatment of Bipolar Disorder

Goodwin FK Jamison KR . Manic-depressive illness. New York: Oxford University Press; 1990.

American Psychiatric Association. Practice guidelines for the treatment of patients with bipolar disorder. Am J Psychiatry 1994;151(Suppl):1S–36S.

Calabrese JR Wayshville MJ . A medication algorithm for treatment of bipolar rapid cycling. J Clin Psychiatry 1995;56(3 Suppl):11S–18S.

Esparon J Kollori J Naylor GJ McHarg AM Smith AHW Hopewood SE . Composition of the prophylactic action of flupenthixol with placebo in lithium treated manic depressive patients. Br J Psychiatry 1986;148:732–5.

Chouinard G Jones B Remington G Bloom D Addington D MacEwan GW , and others. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25–40.

Zarate C Toren M Banov M Weiss M Cole J. Is clozapine a mood stabilizer? J Clin Psychiatry 1995;56:108–12.

Marder SR Meiback RC . Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:6.

Leysen JE Gommeren W Eens A de Chaffoy de Courcelle D Stoof JC , and others. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988;247:661–70.

Kane J Honigfeld G Singer J Meltzer H. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789–96.

Singh AN Catalan J. Risperidone in HIV-related manic psychosis. Lancet 1994;344:1029–30.

Goodnick PJ . Risperidone treatment of refractory acute mania. J Clin Psychiatry. 1995;56:9.

Dwight MM Keck PEJ Stanton SP Strokowski SM McElroy SL . Anti-depressant activity and mania associated with risperidone treatment of schizoaffective disorder. Lancet 1994;344:554–5.

Ereshefsky L Lacombe S. Pharmacological profile of risperidone. Can J Psychiatry 1993;38(3 Suppl):80S–88S.

Janssen PAJ Niemegeers CJE Awouter F Schellekens KHL Megens AAHP Meert TF . Pharmacology of risperidone (R64 766), a new antipsychotic with serotonin-S, and dopamine-D2 antagonist properties. J Pharmacol Exp Ther 1988;244:683–93.

Meltzer HY Matsubara S Lee JC . Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2, pK, values. J Pharmacol Exp Ther 1989;251:238–49.

Bleich A Brown SL Kahn R van Praag HM . The role of serotonin in schizophrenia. Schizophr Bull 1988;14:297–315.

Reyntjens A Gelders YG Hoppenbrouwers M-LJA Vanden Bussche G. Thymosthenic effects of ritanserin (R55667), a centrally acting serotonin-S2 receptor blocker. Drug Development and Research 1986;8:205–11.

Bersani G Crispini A Marini S Pasini A Valducci M Ciani N. Neuroleptic-induced extrapyramidal side effects: Clinical perspectives with ritanserin (R55667), a new selective 5-HT2 receptor blocking agent. Curr Ther Res 1986;40:492–9.